SecurityPTX / Pernix Therapeutics Holdings, Inc. (71426V108)
Chairman of Board and CEOSedor John A
IndustryPharmaceutical Preparations
Institutional Owners36
Institutional Shares2,263,616 - 16.26%
Common Shares Outstanding13,920,264 shares (as of 2018-06-30)
Institutional Value$ 5,249,000 USD

Institutional Stock Ownership and Shareholders

PTX / Pernix Therapeutics Holdings, Inc. Institutional Ownership

Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) has 36 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,263,616 shares. Largest shareholders include Renaissance Technologies LLC, Vanguard Group Inc, BlackRock Inc., Aisling Capital LLC, BlackRock Institutional Trust Company, N.A., Jacobs Levy Equity Management, Inc, Bank Of Montreal /can/, Bank Of Montreal /can/, Geode Capital Management, Llc, and Cetera Investment Advisers.
Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR Shanda Payment Holdings Ltd. 1,000 0 -100.00 2 0 -100.00
2018-08-13 13F-HR GROUP ONE TRADING, L.P. Call 5,400 4,300 -20.37 13 10 -23.08
2018-10-12 13F-HR BANK OF MONTREAL /CAN/ Put 63,000 65,100 3.33 153 63 -58.82
2018-08-13 13F-HR Aisling Capital LLC 210,000 210,000 0.00 502 510 1.59
2018-07-30 13F-HR/A Virtu Financial LLC 46,610 0 -100.00 111 0 -100.00
2018-08-13 13F-HR Renaissance Technologies LLC 941,250 2,250
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 0 12,022 0 29
2018-07-30 13F-HR SIMPLEX TRADING, LLC 1,703 1,066 -37.40 4 2 -50.00
2018-08-14 13F-HR SIGNATUREFD, LLC 96 96 0.00 0 0
2018-08-09 13F-HR BlackRock Inc. 209,448 222,330 6.15 500 540 8.00
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 1,102 11 -99.00 3 0 -100.00
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 0 21,700 0 53
2017-02-10 13F-HR BlackRock Fund Advisors 135,144 17,315 -87.19 84 34 -59.52
2018-08-03 13F-HR SEI INVESTMENTS CO 5 5 0.00 0 0
2018-08-13 13F-HR Stratos Wealth Partners, LTD. 5 0 -100.00 0 0
2018-08-14 13F-HR/A CITADEL ADVISORS LLC Call 15,700 42,000 167.52 38 102 168.42
2018-08-13 13F-HR GROUP ONE TRADING, L.P. Put 1,500 0 -100.00 4 0 -100.00
2018-10-12 13F-HR BANK OF MONTREAL /CAN/ 63,000 65,100 3.33 153 63 -58.82
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 15,124 0 -100.00 36 0 -100.00
2018-10-10 13F-HR LINCOLN CAPITAL CORP 17,000 16
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 39,595 47,126 19.02 94 114 21.28
2018-07-18 13F-HR Bedel Financial Consulting, Inc. 7 7 0.00 0 0
2018-08-13 13F-HR GROUP ONE TRADING, L.P. 9,585 10,521 9.77 23 26 13.04
2018-08-14 13F-HR BARCLAYS PLC 61 58 -4.92 0 0
2018-08-14 13F-HR JACOBS LEVY EQUITY MANAGEMENT, INC 79,921 87,643 9.66 191 213 11.52
2018-08-14 13F-HR GOLDMAN SACHS GROUP INC 15,701 15,008 -4.41 38 36 -5.26
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 176 176 0.00 0 0
2017-02-10 13F-HR BlackRock Advisors LLC 7,631 763 -90.00 5 1 -80.00
2018-08-14 13F-HR VANGUARD GROUP INC 373,449 374,217 0.21 892 909 1.91
2018-08-14 13F-HR VALLEY NATIONAL ADVISERS INC 6 6 0.00 0 0
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 1,610,542 161,054 -90.00 1,002 312 -68.86
2018-07-30 13F-HR SIMPLEX TRADING, LLC Call 4 0 -100.00 0 0
2018-08-16 13F-HR Nelson, Van Denburg & Campbell Wealth Management Group, LLC 70 70 0.00 0 0
2018-08-14 13F-HR ROYAL BANK OF CANADA 103 225 118.45 0 0
2018-08-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 14 14 0.00 0 0
2018-08-14 13F-HR Cetera Investment Advisers 46,750 46,750 0.00 112 113 0.89
2018-08-13 13F-HR Advisor Group, Inc. 177 177 0.00 0 0
2018-08-14 13F-HR UBS Group AG 6,516 0 -100.00 16 0 -100.00
2018-08-07 13F-HR IFP Advisors, Inc 250 250 0.00 1 1 0.00
2018-08-13 13F-HR WOLVERINE TRADING, LLC Put 15,900 15,900 0.00 38 38 0.00
2018-09-18 13F-HR/A NORTHERN TRUST CORP 12,435 16,699 34.29 29 40 37.93
2018-08-14 13F-HR MORGAN STANLEY 2,089 3,311 58.50 5 8 60.00
2018-08-10 13F-HR NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 7 7 0.00 0 0
2017-01-13 13F-HR MetLife Securities, Inc 123 13 -89.43 0 0
2018-07-19 13F-HR Searle & Co. 13,325 13,325 0.00 32 32 0.00
2018-07-30 13F-HR SIMPLEX TRADING, LLC Put 1 14 1,300.00 0 3
2018-08-14 13F-HR DEUTSCHE BANK AG\ 1 1 0.00 0 0
2018-08-14 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 0 12,600 0 31
PTX : Pernix Therapeutics Holdings Stock Analysis and Research Report

2017-10-16 - Asif

Pernix Therapeutics is a specialty pharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. Its strategy is to continue to create shareholder value by: growing sales of the existing products in its portfolio in various ways, including identifying new growth opportunities; and acquiring additional marketed specialty products or products close to regulatory approval to leverage its existing expertise and infrastructure. Pernix Therapeutics target underserved segments, such as central nervous system (CNS) indications, including neurology, pain and psychiatry. The company promote its core branded products to physicians through its sales forces. The company market its generic products through its wholly owned subsidiaries, Macoven and Cypress. Its branded products include Treximet, a medication indicated for the acute treatment of migraine attacks, with or without aura, ...

Related News Stories

Pernix Therapeutics Holdings, Inc. (PTX) CEO John Sedor on Q2 2018 Results - Earnings Call Transcript

2018-08-09 seekingalpha
Pernix Therapeutics Holdings, Inc. (NYSEMKT:PTX) Q2 2018 Earnings Conference Call August 9, 2018 4:30 PM ET (0-2)

Pernix Therapeutics Buys Bankrupt Orexigen’s Weight Loss Drug for $73.5 Million

2018-07-31 biospace
In March, San Diego-based Orexigen Therapeutics filed for bankruptcy. Back in April, Orexigen entered into an asset purchase deal with Nalpropion Pharmaceuticals to sell most of its assets, subject to court approval. Under that deal, Orexigen would sell global rights to Contrave (naltrexone HCl/bupropion HCL extended release)/Mysimba (naltrexone HCl and bupropion HCL prolonged release) and other assets. (0-1)

Pernix Therapeutics' (PTX) CEO John Sedor on Q1 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Pernix Therapeutics Holdings, Inc. (NYSEMKT:PTX) Q1 2018 Earnings Conference Call May 10, 2018 4:30 PM ET (28-1)

Orexigen Enters into Agreement to Sell Company to Newly Formed Entity Nalpropion Pharmaceuticals

2018-04-24 biospace
One month after filing for bankruptcy anti-obesity company Orexigen Therapeutics, Inc. could be acquired by the newly-formed company Nalpropion Pharmaceuticals, Inc. for $75 million in cash. (28-8)

BRIEF-Pernix Therapeutics Announces Participation In Lead Bid Worldwide Rights Of Contrave

2018-04-23 reuters
* PERNIX THERAPEUTICS ANNOUNCES PARTICIPATION IN LEAD BID FOR ACQUISITION OF WORLDWIDE RIGHTS TO CONTRAVE® FOR WEIGHT LOSS (21-0)

CUSIP: 71426V108